

# Sergio Bracarda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2731558/publications.pdf>

Version: 2024-02-01

148  
papers

18,885  
citations

66315

42  
h-index

11928

134  
g-index

157  
all docs

157  
docs citations

157  
times ranked

16444  
citing authors

#	ARTICLE	IF	CITATIONS
1	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	1.0	7
2	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	2.0	11
3	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	1.6	17
4	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	5
5	The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	1
6	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
7	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	1.7	4
8	Ad hoc afatinib in an elderly lung cancer patient with EGFR exon 19 deletion L747-A750>P. <i>Advances in Respiratory Medicine</i> , 2022, 90, 234-235.	0.5	0
9	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 498.e1-498.e9.	0.9	3
10	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	0.9	64
11	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e84-e91.	0.9	23
12	How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. <i>World Journal of Urology</i> , 2021, 39, 1445-1452.	1.2	0
13	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	1.3	81
14	Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. <i>Scientific Reports</i> , 2021, 11, 7150.	1.6	12
15	Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. <i>Clinical and Translational Imaging</i> , 2021, 9, 215-220.	1.1	5
16	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
17	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
18	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24

#	ARTICLE	IF	CITATIONS
19	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	1.8	14
20	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 131-142.	6.3	167
21	Laparoscopic Compared with Open D2 Gastrectomy on Perioperative and Long-Term, Stage-Stratified Oncological Outcomes for Gastric Cancer: A Propensity Score-Matched Analysis of the IMIGASTRIC Database. <i>Cancers</i> , 2021, 13, 4526.	1.7	6
22	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	1.3	13
23	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110543.	0.9	3
24	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , 2021, 22, 1669-1680.	5.1	73
25	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 199-206.	2.0	20
26	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 105-120.	5.1	61
27	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
28	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	1.7	28
29	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	1.4	14
30	Patients with sarcomatoid renal cell carcinoma “re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	1.3	47
31	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
32	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. <i>ESMO Open</i> , 2020, 5, e000652.	2.0	23
33	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. <i>Bladder Cancer</i> , 2020, 6, 43-52.	0.2	2
34	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	0.9	15
35	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	1.3	85
36	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	2.1	9

#	ARTICLE	IF	CITATIONS
37	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2506-2514.	3.2	20
38	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU International, 2020, 126, 73-82.	1.3	19
39	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	1.3	45
40	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	13
41	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Tj ETQq1 1 0.784314 rgBT /Overlook 2020, 72, 595-604.	3.9	10
42	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	1.3	1
43	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research, 2019, 25, 928-936.	3.2	232
44	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU International, 2019, 123, 98-105.	1.3	70
45	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. Critical Reviews in Oncology/Hematology, 2019, 139, 149-157.	2.0	10
46	Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. Tumori, 2019, 105, 161-167.	0.6	2
47	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	5.1	594
48	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	2.0	15
49	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2019, 105, 3-12.	0.6	10
50	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
51	Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. Clinical Genitourinary Cancer, 2019, 17, e689-e703.	0.9	12
52	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Frontiers in Oncology, 2019, 9, 228.	1.3	20
53	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	1.9	131
54	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. BMC Cancer, 2019, 19, 283.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) <a href="#">TJ ETQq1 1 0.784314 rgBT / @verlock</a>	1.7	1
56	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019, 11, 1908.	0.8	8
57	Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. <i>Oncotarget</i> , 2019, 10, 4161-4168.	0.7	0
58	No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases. <i>Annals of Translational Medicine</i> , 2019, 7, 612-612.	2.0	8
59	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 51-59.	13.9	3,334
60	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	0.8	117
61	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-772.	1.1	9
62	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018, 14, 1347-1354.	1.0	24
63	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 122.	0.9	0
64	“To Cut or Not to Cut”, a Biomolecular Approach to Metastasectomy in Metastatic Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 481-482.	15.2	900
65	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	0.8	12
66	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	0.8	164
67	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	1.1	18
68	How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 227-233.	5.1	1,388
69	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 312-322.	3.4	56
70	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017, 55, 71-82.	1.4	26
71	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 165-172.	6.3	153
72	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.		

#	ARTICLE	IF	CITATIONS
73	Editorial Comment. Journal of Urology, 2017, 198, 536-537.	0.2	0
74	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus, 2017, 3, 321-324.	1.6	15
75	Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule. Frontiers in Pharmacology, 2017, 8, 523.	1.6	9
76	The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance. International Journal of Molecular Sciences, 2017, 18, 1512.	1.8	7
77	New Frontiers in Treatment. , 2017, , 209-221.		0
78	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	14
79	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. European Journal of Cancer, 2016, 69, 226-235.	1.3	65
80	IMA901, a multi-peptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	5.1	181
81	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical Genitourinary Cancer, 2016, 14, 406-414.	0.9	8
82	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. Critical Reviews in Oncology/Hematology, 2016, 98, 254-263.	2.0	2
83	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer, 2015, 51, 1293-1302.	1.3	45
84	REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis. Future Oncology, 2015, 11, 2893-2903.	1.1	3
85	Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused. European Urology, 2015, 67, 680-681.	0.9	3
86	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	3.5	65
87	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
88	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	1.7	49
89	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. Oncology, 2015, 88, 273-280.	0.9	24
90	Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies. Seminars in Oncology, 2015, 42, 495-505.	0.8	44



#	ARTICLE	IF	CITATIONS
91	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation. <i>Future Oncology</i> , 2015, 11, 3083-3090.	1.1	8
92	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 50-59.	2.0	14
93	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.2	58
94	Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 497-510.	1.0	9
95	Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1283-1294.	1.1	11
96	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	51
97	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	1.1	43
98	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	1.1	12
99	Prostate changes related to therapy: with special reference to hormone therapy. <i>Future Oncology</i> , 2014, 10, 1873-1886.	1.1	3
100	Poor Survival in Prostate Cancer Patients with Primary Refractoriness to Docetaxel. <i>European Urology</i> , 2014, 65, 505-507.	0.9	20
101	GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 386-393.	2.0	18
102	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 262-269.	0.9	9
103	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. <i>European Journal of Cancer</i> , 2014, 50, 1090-1099.	1.3	88
104	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	1.3	133
105	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY). <i>European Urology</i> , 2013, 63, 254-261.	0.9	29
106	Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program. <i>Urology</i> , 2013, 81, 143-149.	0.5	16
107	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	1.1	66
108	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013, 31, 189-189.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naïve metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.. Journal of Clinical Oncology, 2013, 31, 356-356.	0.8	3
110	Retrospective analysis of sorafenib as first or second target therapy in mRCC patients in Italian centers: An update.. Journal of Clinical Oncology, 2013, 31, e15524-e15524.	0.8	0
111	Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).. Journal of Clinical Oncology, 2013, 31, e16093-e16093.	0.8	0
112	Biologic tools to personalize treatment in genitourinary cancers. Critical Reviews in Oncology/Hematology, 2012, 84, e42-e48.	2.0	2
113	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	3.4	9
114	Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group. Critical Reviews in Oncology/Hematology, 2012, 82, 378-386.	2.0	25
115	Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. European Urology, 2012, 61, 11-25.	0.9	206
116	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. European Urology, 2012, 61, 826-833.	0.9	59
117	Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey.. Journal of Clinical Oncology, 2012, 30, 4627-4627.	0.8	3
118	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 253-253.	0.8	3
119	PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).. Journal of Clinical Oncology, 2012, 30, 4541-4541.	0.8	45
120	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology, 2012, 30, e15112-e15112.	0.8	0
121	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon- $\alpha$ 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International, 2011, 107, 214-219.	1.3	43
122	Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU International, 2011, 107, 13-20.	1.3	35
123	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 2011, 117, 501-509.	2.0	126
124	Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, 2010, 116, 4256-4265.	2.0	1,039
125	Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. Journal of Clinical Oncology, 2010, 28, 2144-2150.	0.8	767
126	Redefining the role of interferon in the treatment of malignant diseases. European Journal of Cancer, 2010, 46, 284-297.	1.3	85



#	ARTICLE	IF	CITATIONS
127	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. <i>BMC Cancer</i> , 2010, 10, 675.	1.1	18
128	Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape. <i>European Urology Supplements</i> , 2009, 8, 787-792.	0.1	4
129	Current and Future Treatment Options for Metastatic Renal Cell Carcinoma. <i>European Urology Supplements</i> , 2009, 8, 799-808.	0.1	4
130	Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma. <i>European Urology Supplements</i> , 2009, 8, 815-819.	0.1	2
131	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	5.1	571
132	2-Fluoroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells. <i>Prostate</i> , 2008, 68, 360-372.	1.2	4
133	Editorial Comment on: Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. <i>European Urology</i> , 2008, 53, 331.	0.9	0
134	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet</i> , The, 2008, 372, 449-456.	6.3	2,848
135	IGC* Practice Guidelines on Germ Cell Tumor in Adult Male Patients. <i>Tumori</i> , 2008, 94, 96-109.	0.6	12
136	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. <i>Lancet</i> , The, 2007, 370, 2103-2111.	6.3	2,140
137	The medical management of prostate cancer: a multidisciplinary team approach. <i>BJU International</i> , 2007, 99, 22-27.	1.3	36
138	Editorial Comment on: Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study. <i>European Urology</i> , 2007, 52, 1698-1699.	0.9	0
139	Targeting of EGFR tyrosine kinase by ZD1839 (Iressa) in androgen-responsive prostate cancer in vitro. <i>Molecular Genetics and Metabolism</i> , 2006, 88, 114-122.	0.5	20
140	Mechanism of 2-chloroadenosine toxicity to PC3 cell line. <i>Prostate</i> , 2006, 66, 1425-1436.	1.2	9
141	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 379-396.	2.0	89
142	Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer. <i>Lung Cancer</i> , 2002, 37, 79-85.	0.9	13
143	Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma. , 2000, 88, 1438-1444.		30
144	Ondansetron. <i>European Journal of Cancer</i> , 1993, 29, S16-S21.	1.3	10

#	ARTICLE	IF	CITATIONS
145	Reliability and validity of a quality of life questionnaire in cancer patients. <i>European Journal of Cancer</i> , 1993, 29, S63-S69.	1.3	7
146	Antiemetic Activity of Two Different High Doses and Schedules of Metoclopramide in Dacarbazine-Treated Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1992, 15, 112-114.	0.6	2
147	Predictive Factors of Delayed Emesis in Cisplatin-Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, 238-242.	0.6	106
148	A Double-Blind Trial Comparing Antiemetic Efficacy and Toxicity of Metoclopramide Versus Methylprednisolone Versus Domperidone in Patients Receiving Doxorubicin Chemotherapy Alone or in Combination with Other Antiproliferative Agents. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988, 11, 594-596.	0.6	23